Pharma Journalist -

2nd Combination Products Lifecycle Management, Boston, April 23: Increasingly fierce competition amongst pharma/biotechs and R&D costs have made drug and device developers…
Read More...

On April 19, 2019, the Food and Drug Administration approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) plus axitinib for the first-line treatment of patients with advanced renal…
Read More...

Oakrum Pharma, LLC (Oakrum) announced that it has entered into an agreement with Biophore India Pharmaceuticals Pvt. Ltd. (Biophore) to develop and manufacture two prescription generic…
Read More...

Elpiscience BioPharma and Bio-Techne Corporation announced that the companies have entered into a strategic collaboration for the development of anti-cancer therapeutics. Under the…
Read More...

Eli Lilly and Company and Avidity Biosciences, Inc. announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new…
Read More...

Teva Pharmaceutical Industries Ltd. announced the launch of a generic version of VESIcare ®1 (solifenacin succinate) Tablets, 5 mg and 10 mg, in the U.S. Solifenacin Succinate…
Read More...

Pfizer Inc. and Eli Lilly and Company announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg. The objective of the study was to compare the long-term joint…
Read More...

Non-profit drug developer, TB Alliance, and pharmaceutical company, Mylan N.V. announced a global collaboration to make the experimental drug pretomanid accessible for use in two…
Read More...

Ipsen and Clementia Pharmaceuticals announced the closing of Ipsen’s acquisition of Clementia following approval of the arrangement by Clementia shareholders and the Quebec Superior…
Read More...

Significant increase in exhibitors driven by bio growth at bioLIVE and separate nutraceuticals event. Shanghai, 8th April 2019: CPhI & P-MEC China (#CPhIChina and #PMECChina) –…
Read More...